BioNJ Diagnostics & Personalized Medicine Survey

 

For a long time, the BioNJ D&PM Committee has been working with leaders in our industry and members of our organization to develop a clear understanding of how the shifting value proposition of RX to DX and the transition to Companion and Therapeutic Diagnostics will positively impact global health care. The Committee is dedicated to the work of communication, education and partnering in order to position New Jersey as the best location in the world for the development and growth of Personalized Medicine. Our goal is to provide our members with world class opportunities to acquire the tools, gain the access and create the partnerships necessary to meet the convergence challenges between RX, DX and Health 2.0.

Below please find a very brief questionnaire. Your feedback is essential to helping the D&PM Committee evaluate basic levels of thought, needs and priorities with regard to the emergence of Personalized Medicine.